Onychomycosis Market Report and Forecast 2024-2032

The onychomycosis market size was valued at USD 4 billion in 2023, driven by prevalence of onychomycosis and related conditions. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 6.3 billion by 2032.

Onychomycosis: Introduction

Onychomycosis is a fungal infection that primarily affects the toenails and, less frequently, the fingernails. It is characterized by changes in nail color, thickness, and texture, often resulting in yellow, brittle, or thickened nails. The condition is caused by various fungi, with dermatophytes being the most common culprits. It is more prevalent in older adults and can be exacerbated by factors like diabetes, weakened immune systems, and poor circulation. Onychomycosis is not just a cosmetic issue; it can lead to discomfort and pain, particularly when wearing shoes, and can also spread to other nails or skin. Treatment often involves antifungal medications, either topical or oral, and can take several months for complete nail recovery.

Key Trends in the Onychomycosis Market

The growth of the onychomycosis market is largely driven by the rising incidence of the condition and increased awareness about its treatment. The infection's impact on social and psychological well-being emphasizes the need for effective treatments. Organizations like the Global Nail Fungus Organization and government initiatives like the CDC's Think Fungus campaign are working to increase awareness and improve prevention and treatment strategies, which in turn is boosting the demand for onychomycosis therapeutics.

Drugs remain the primary choice for onychomycosis treatment due to their high success rate. Commonly used drugs include terbinafine, ciclopirox, Jublia, and Fluconazole. The market is expected to continue favouring drugs due to their effectiveness and accessibility. Notably, new drugs are being approved, such as Tavaborole Topical Solution by Lupin, enhancing treatment options.

The distal subungual onychomycosis segment has been particularly dominant, likely due to its increasing prevalence and the number of generic drug approvals by regulatory agencies like the FDA. On the other hand, the topical treatment segment is expected to witness the fastest growth, attributed to the ease of use and administration, leading to higher patient compliance.

Pharmaceutical companies are focusing on acquiring specialized capabilities and forming strategic collaborations and partnerships to develop novel therapies for onychomycosis. This includes efforts to improve patient compliance and reduce therapy costs, as seen with the launch of highly bioavailable formulations like Intas Pharmaceuticals' Super Bioavailable Itraconazole. Such initiatives are crucial in maintaining competitive positions in the market and addressing specific treatment concerns.

The onychomycosis treatment market is fragmented and highly competitive, with major players like Bausch Health, Galderma SA, Novartis, and Pfizer playing significant roles. These companies focus on development, collaboration, and product launches to strengthen their market positions. For example, the FDA's expanded approval of Jublia by Bausch Health for treating onychomycosis indicates ongoing efforts to enhance treatment options.

Global Onychomycosis Market Segmentation

Market Breakup by Treatment Type

• Drugs
• Laser Therapy
• Photodynamic Therapy
• Others

Market Breakup by Type

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Other Types

Market Breakup by Route of Administration

• Oral
• Topical

Market Breakup by End User

• Hospitals
• Dermatology and Podiatry Clinics
• Offline Pharmacies
• Online Stores

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan

Onychomycosis Market Overview

North America, particularly the United States, holds a substantial market share. Factors contributing to this include high drug costs, a growing elderly population, and an increasing number of onychomycosis and diabetic patients. Age-related factors like nail trauma and poor circulation contribute to the prevalence of onychomycosis in this region. The market dynamics have been influenced by strategies like research and development, mergers, acquisitions, and new product launches by major pharmaceutical companies.

Europe, including the United Kingdom and the EU-4 countries (Germany, France, Italy, and Spain), is expected to see significant growth in the onychomycosis market. This growth is attributed to favorable health reimbursement policies, high-quality healthcare infrastructure, and an increasing geriatric population, which is more susceptible to onychomycosis. The European market is also characterized by ongoing research and development in the field of onychomycosis treatments.

The onychomycosis market in Japan is part of the broader Asia-Pacific market, which is emerging rapidly. This growth is driven by increasing awareness, improving healthcare infrastructure, and rising investments in healthcare. The Asia-Pacific region, including Japan, is expected to show significant growth in the onychomycosis market, owing to these factors.

Onychomycosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Bayer AG
• Pfizer Inc.
• Abbott
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• GSK Plc.

The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


This product will be delivered within 5-7 business days.